OXER1 Antibody

What is OXER1 and why is it significant for immunological research?

OXER1 (oxoeicosanoid receptor 1) is a G-protein coupled receptor deorphanized in 1993 as the specific receptor for the arachidonic acid metabolite 5-oxo-ETE (5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid) . Recent research has revealed that OXER1 also functions as a membrane androgen receptor, binding testosterone and triggering membrane-mediated cellular actions including migration, apoptosis, proliferation, and Ca2+ mobilization .

The receptor has emerged as significant in immunological research due to its expression in various immune cells and its role in inflammatory processes. It is highly expressed in neutrophils, with moderate expression in lymphocytes and monocytes, and its expression can be upregulated by inflammatory stimuli such as lipopolysaccharide (LPS) . OXER1's involvement in eosinophil chemotaxis makes it particularly relevant for studying allergic and inflammatory conditions .

What are the recommended applications for OXER1 antibodies in laboratory settings?

Based on validated applications from commercial antibodies, OXER1 antibodies are primarily useful for:

For optimal results, researchers should validate the antibody in their specific experimental system, as performance may vary between tissue types and cell lines .

How should researchers optimize Western blot protocols for OXER1 detection?

For optimal Western blot detection of OXER1:

• Sample preparation: Use cell lysis buffers containing protease inhibitors to prevent degradation of OXER1 protein. K-562 and MCF-7 cell lysates have been validated as positive controls .

• Protein loading: Load 20-50 μg of total protein per lane to ensure sufficient OXER1 detection.

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal separation of OXER1 (43-46 kDa).

• Transfer conditions: Transfer at 100V for 60-90 minutes using standard transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol).

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute anti-OXER1 antibody 1:500-1:1000 in blocking buffer and incubate overnight at 4°C.

• Washing: Perform 3-4 washes with TBST, 5-10 minutes each.

• Detection system: Use HRP-conjugated secondary antibodies with appropriate species reactivity (typically anti-rabbit IgG for polyclonal antibodies).

• Expected band size: Look for bands at 43-46 kDa, which is the observed molecular weight range for OXER1 .

What tissue and cell types are suitable positive controls for OXER1 antibody validation?

Based on published research, the following samples serve as reliable positive controls for OXER1 antibody validation:

Cell lines:

• K-562 cells (human myelogenous leukemia cells)

• MCF-7 cells (human breast cancer cell line)

• DU-145 cells (human prostate cancer cells, high expression)

• THP-1 cells (human monocytic leukemia cell line)

Primary cells:

• Human neutrophils (highest expression among leukocytes)

• Human monocytes and macrophages

• Human lymphocytes (moderate expression)

Tissue samples:

• Human kidney tissue

• Human liver tissue

• Prostate cancer tissue specimens

When validating a new OXER1 antibody, researchers should include at least one of these established positive controls alongside appropriate negative controls (e.g., isotype controls or OXER1 knockdown samples).

How can researchers effectively assess OXER1 expression changes in response to inflammatory stimuli?

To effectively monitor OXER1 expression changes during inflammation:

• Experimental design: Implement a time-course study with appropriate inflammatory stimuli. Based on published research, LPS treatment significantly increases OXER1 expression, particularly in monocytes .

• Multi-level analysis: Combine techniques to assess changes at both mRNA and protein levels:

  • qRT-PCR for mRNA quantification (primer sequences: Forward: 5′-CAG TGG CTG CGA GAA TGC TGA TG-3′; Reverse: 5′-TGG GAA TGC CAT CCT GGA CAC-3′)

  • Western blot for protein expression (use GAPDH or β-actin as loading controls)

  • Flow cytometry for cell surface vs. intracellular expression changes

  • Immunofluorescence for spatial distribution changes

• Functional validation: Couple expression analysis with functional assays such as calcium mobilization or cAMP production to confirm that expression changes correlate with functional responses .

• Controls: Include positive controls (cells known to express high levels of OXER1) and negative controls (OXER1 knockdown cells or isotype control antibodies) .

This multi-modal approach provides a comprehensive assessment of how inflammatory stimuli affect OXER1 expression and function.

What methodological approaches can resolve discrepancies between OXER1 mRNA and protein expression in cancer tissues?

Researchers studying OXER1 in cancer have observed discrepancies between mRNA and protein expression levels, particularly in prostate cancer specimens . To address this methodological challenge:

• Combined analysis approach: Implement parallel analysis of:

  • mRNA levels via qRT-PCR

  • Protein levels via immunohistochemistry, Western blot, and flow cytometry

  • Functional activity via ligand binding assays (e.g., fluorescent testosterone-BSA binding)

• Tissue heterogeneity considerations:

  • Account for tissue composition by quantifying epithelial/stromal/immune cell ratios in samples

  • Use laser capture microdissection to isolate specific cell populations

  • Perform dual immunofluorescence staining for OXER1 and cell-type specific markers

• Post-transcriptional regulation assessment:

  • Examine mRNA stability and half-life using actinomycin D chase experiments

  • Assess microRNA involvement using prediction algorithms and validation experiments

  • Investigate protein degradation rates using proteasome inhibitors

• Sample processing standardization:

  • Use consistent fixation methods and processing times

  • Implement antigen retrieval optimization, comparing citrate buffer (pH 6.0) with TE buffer (pH 9.0)

  • Process paired normal/tumor samples identically

• Statistical approach:

  • Analyze larger sample sizes to account for biological variation

  • Stratify samples based on clinical parameters and molecular subtypes

  • Apply multivariate analysis to identify factors affecting OXER1 expression

By implementing these methodological approaches, researchers can better understand the biological significance of discrepancies between OXER1 mRNA and protein expression in cancer tissues.

How can researchers develop robust experimental designs to evaluate OXER1 antagonists in cellular systems?

Based on published experimental frameworks for OXER1 antagonist evaluation , researchers should implement the following comprehensive approach:

• In silico screening and selection:

  • Utilize molecular docking to identify compounds with predicted binding to OXER1

  • Apply QSAR (Quantitative Structure-Activity Relationship) models to distinguish potential antagonists from agonists

  • Select compounds with Gαi-GDP binding energies > -666 kcal/mol (indicative of antagonistic properties)

• Primary functional assay development:

  • cAMP production assay: As OXER1 couples to Gαi, measure inhibition of forskolin-stimulated cAMP production

  • Experimental setup:

    • Pretreat cells with test compounds (10^-6 M) for 15 min at 37°C

    • Add 5-oxo-ETE (10^-7 M) and forskolin (15 μM)

    • Measure cAMP levels using a competitive immunoassay

    • Express results as % reversion of 5-oxo-ETE effect

• Secondary functional validation:

  • Intracellular Ca^2+ mobilization: Measure using fluorescent Ca^2+ indicators

  • Actin cytoskeleton rearrangement: Assess using fluorescently labeled phalloidin

  • Cell migration: Quantify using wound healing or transwell migration assays

  • These assays distinguish between full and partial antagonists

• Controls and comparative analysis:

  • Positive control: Testosterone (known OXER1 antagonist)

  • Negative control: Vehicle (DMSO)

  • Reference compounds: Known polyphenolic OXER1 antagonists

• Dose-response characterization:

  • Test compounds across concentration range (10^-9 to 10^-5 M)

  • Calculate IC50 values for inhibition of 5-oxo-ETE effects

  • Generate Schild plots to determine competitive vs. non-competitive antagonism

• Selectivity profiling:

  • Test against related receptors

  • Evaluate effects on other signaling pathways

This comprehensive experimental design allows for robust evaluation of potential OXER1 antagonists and characterization of their pharmacological properties.

What are the critical considerations for developing immunohistochemical protocols to detect OXER1 in formalin-fixed, paraffin-embedded cancer tissues?

Developing effective IHC protocols for OXER1 in FFPE cancer tissues requires addressing several critical factors:

• Fixation and processing considerations:

  • Standardize fixation time (12-24 hours in 10% neutral buffered formalin)

  • Minimize cold ischemia time (<1 hour between tissue excision and fixation)

  • Use consistent tissue processing protocols to prevent artifacts

• Antigen retrieval optimization:

  • Primary recommendation: Heat-induced epitope retrieval using TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Optimization experiment:

    Retrieval Method	Buffer	pH	Time	Temperature
    Heat-induced	TE	9.0	20 min	95-98°C
    Heat-induced	Citrate	6.0	20 min	95-98°C
    Enzymatic	Proteinase K	N/A	10-20 min	37°C

• Antibody validation strategy:

  • Test multiple antibody clones/lots on positive control tissues (kidney, liver)

  • Include known positive cell lines (e.g., DU-145 cells) as tissue microarray controls

  • Validate specificity using peptide competition and OXER1 knockdown controls

  • Determine optimal antibody concentration (typically 1:20-1:200 dilution)

• Detection system selection:

  • For low-expression samples: High-sensitivity polymer detection systems

  • For quantitative analysis: Chromogenic vs. fluorescent multiplexing options

  • For co-localization studies: Multi-color immunofluorescence

• Interpretation challenges:

  • Establish clear scoring criteria (membrane vs. cytoplasmic staining)

  • Account for heterogeneous expression within tumors

  • Distinguish OXER1 expression in tumor cells vs. tumor-infiltrating immune cells

  • Implement digital image analysis for objective quantification

• Validation across multiple specimens:

  • Test protocol on tissue microarrays containing multiple tumor types

  • Include matched normal/tumor pairs when possible

  • Correlate IHC findings with other detection methods (e.g., membrane testosterone-BSA binding)

By addressing these critical considerations, researchers can develop robust IHC protocols for reliable detection and interpretation of OXER1 expression in cancer tissues.

How can researchers effectively design experiments to investigate the newly discovered redox-sensing function of OXER1?

Recent research has revealed that OXER1 functions as a tissue redox sensor with protective effects against oxidative stress . To effectively investigate this novel function, researchers should consider the following experimental design approach:

• Model systems selection:

  • Human cell lines: Intestinal epithelial cells (e.g., Caco-2) show OXER1-dependent protection against H₂O₂-induced apoptosis

  • Animal models: Consider zebrafish larvae with hcar1-4 (OXER1 ortholog) knockout, which show baseline intestinal inflammation

  • Primary human cells: Compare redox responses in cells with varying OXER1 expression levels

• OXER1 manipulation strategies:

  • Genetic approaches:

    • siRNA/shRNA knockdown of OXER1

    • CRISPR-Cas9 knockout of OXER1

    • Overexpression of wild-type and mutant OXER1

  • Pharmacological approaches:

    • 5-KETE (OXER1 agonist) treatment

    • OXER1 antagonists (e.g., ZINC15959779)

• Oxidative stress induction methods:

  • H₂O₂ treatment (250-500 μM, 1-24 hours)

  • Antimycin A (mitochondrial ROS inducer)

  • Hypoxia/reoxygenation protocols

  • Inflammatory stimuli (e.g., TNF-α, LPS)

• Experimental readouts:

  • Cell death/apoptosis assessment:

    Method	Measurement	Timepoint
    Annexin V/PI	Flow cytometry	1-24h post-stress
    Caspase 3/7	Fluorogenic substrate	4-12h post-stress
    TUNEL	Microscopy	12-24h post-stress

  • Oxidative stress markers:

    • 8-oxo-dG lesions in DNA

    • Protein carbonylation

    • Lipid peroxidation

    • ROS levels (DCF-DA, MitoSOX)

  • Protective enzyme expression:

    • NUDT1/MTH1 (human cells)

    • NUDT15/MTH2 (zebrafish)

    • Other antioxidant systems

• Signaling pathway analysis:

  • Western blot for key signaling proteins

  • Transcriptome analysis comparing control vs. OXER1-manipulated cells under oxidative stress

  • Phosphoproteomics to identify rapid signaling events

• Mechanistic validation experiments:

  • Epistasis experiments (e.g., NUDT1 knockdown + 5-KETE treatment)

  • Rescue experiments with antioxidants

  • Domain mapping of OXER1 to identify regions critical for redox sensing

This comprehensive experimental approach will enable researchers to thoroughly investigate the redox-sensing function of OXER1 and its potential implications for inflammatory and oxidative stress-related diseases.

What are the most effective strategies for resolving non-specific binding issues with OXER1 antibodies?

When encountering non-specific binding with OXER1 antibodies, implement the following systematic troubleshooting approach:

• Antibody validation and selection:

  • Verify antibody specificity using OXER1 knockdown/knockout controls

  • Compare multiple antibodies targeting different epitopes

  • For polyclonal antibodies, consider affinity purification against the immunizing peptide

• Blocking optimization:

  • Test different blocking agents:

    Blocking Agent	Concentration	Incubation Time	Best For
    BSA	1-5%	30-60 min	WB, IF
    Non-fat dry milk	3-5%	30-60 min	WB
    Normal serum	5-10%	30-60 min	IHC, IF
    Commercial blockers	As directed	As directed	Multiple applications

  • Add 0.1-0.3% Triton X-100 for intracellular staining

  • Include 0.05% Tween-20 in washing buffers

• Antibody dilution and incubation conditions:

  • Test serial dilutions (e.g., 1:50, 1:100, 1:200, 1:500, 1:1000)

  • Extend primary antibody incubation (overnight at 4°C vs. 1-2 hours at room temperature)

  • Add 0.1-0.2% BSA to antibody diluent to reduce non-specific binding

• Washing protocol optimization:

  • Increase number of washes (5-6 washes of 5-10 minutes each)

  • Use higher salt concentration in wash buffer (up to 500 mM NaCl)

  • Add 0.05-0.1% Tween-20 to wash buffers

• Technical modifications for specific applications:

  • Western blot:

    • Pre-adsorb antibody with membrane fragments from negative control samples

    • Use gradient gels for better protein separation

    • Reduce antibody concentration and add 5% milk to antibody solution

  • Immunohistochemistry:

    • Quench endogenous peroxidase (3% H₂O₂, 10 min)

    • Block endogenous biotin if using biotin-based detection

    • Perform peptide competition controls

  • Immunofluorescence:

    • Include autofluorescence quenching steps

    • Use Sudan Black B (0.1-0.3%) to reduce background

    • Employ confocal microscopy for improved signal:noise ratio

• Cross-reactivity assessment:

  • Consider species cross-reactivity issues if working with non-human samples

  • Test for cross-reactivity with related GPCRs

  • Validate findings with complementary non-antibody techniques

By systematically implementing these strategies, researchers can effectively minimize non-specific binding issues with OXER1 antibodies across different applications.

How should researchers reconcile contradictory findings between different detection methods for OXER1?

When faced with contradictory results between different OXER1 detection methods, researchers should implement this systematic reconciliation framework:

• Method-specific limitations assessment:

  • Western blot: Potential denaturation affecting epitope recognition

  • IHC/IF: Fixation and antigen retrieval variations

  • Flow cytometry: Cell preparation affecting surface expression

  • mRNA analysis: Post-transcriptional regulation disconnected from protein levels

• Comprehensive cross-validation approach:

  • Technical validation:

    Detection Method	Control Sample	Expected Result	Validation Criteria
    Western blot	K-562 cells	43-46 kDa band	Specific band at expected MW
    qRT-PCR	DU-145 cells	High expression	Specific amplification (melt curve)
    IHC	Kidney tissue	Membrane staining	Pattern matches literature
    Flow cytometry	Neutrophils	High expression	>2-fold above isotype control

  • Biological validation:

    • Test multiple cell lines with reported OXER1 expression

    • Compare normal vs. cancer tissue pairs

    • Analyze primary cells after inflammatory stimulation

• Targeted investigation of discrepancies:

  • For mRNA/protein discrepancies:

    • Assess mRNA stability and translation efficiency

    • Investigate protein turnover rates

    • Examine post-translational modifications

  • For antibody-based detection discrepancies:

    • Compare antibodies targeting different epitopes

    • Validate with peptide competition assays

    • Confirm with genetic approaches (siRNA, CRISPR knockout)

  • For functional vs. expression discrepancies:

    • Investigate receptor sensitivity/desensitization

    • Assess receptor internalization dynamics

    • Examine G-protein coupling efficiency

• Integrated data analysis:

  • Weigh evidence based on methodological strengths/limitations

  • Consider biological context and cellular heterogeneity

  • Analyze data from multiple perspectives (subcellular localization, activity state)

  • Develop hypotheses that reconcile apparent contradictions

• Orthogonal validation approaches:

  • Functional assays (cAMP production, Ca²⁺ mobilization)

  • Ligand binding studies (e.g., testosterone-BSA binding)

  • Proximity ligation assays for protein interactions

  • Newly emerging technologies (e.g., spatial transcriptomics)

By implementing this reconciliation framework, researchers can systematically address contradictory findings between different OXER1 detection methods and develop a more comprehensive understanding of OXER1 biology.

What experimental approaches can evaluate the dual roles of OXER1 in inflammation and redox signaling?

To investigate the emerging dual functionality of OXER1 in both inflammation and redox signaling, researchers should implement a multi-faceted experimental approach:

• Integrated cellular models:

  • Immune-epithelial co-culture systems:

    • Neutrophil or macrophage co-culture with intestinal epithelial cells

    • OXER1 knockdown/overexpression in specific cell types

    • Assessment of redox stress transfer between cell populations

  • 3D organoid models:

    • Intestinal organoids from wild-type vs. OXER1-deficient sources

    • Exposure to inflammatory stimuli and oxidative stressors

    • Analysis of barrier integrity and immune cell recruitment

• Pathway dissection experiments:

  • Signaling bifurcation analysis:

    Pathway Component	Inflammation Readout	Redox Response Readout
    Gαi signaling	Inhibition of cAMP	NUDT1/15 expression
    Gβγ signaling	Ca²⁺ mobilization	Actin rearrangement
    β-arrestin	Receptor internalization	PI3K/Akt activation

  • Selective pathway inhibition:

    • Pertussis toxin (Gαi inhibitor)

    • Gallein (Gβγ inhibitor)

    • PI3K inhibitors (e.g., wortmannin)

    • Assessment of differential effects on inflammatory vs. redox responses

• Temporal dynamics investigation:

  • Time-course experiments:

    • Early signaling events (seconds to minutes)

    • Intermediate responses (minutes to hours)

    • Late adaptive changes (hours to days)

  • Pulse-chase designs:

    • Acute vs. chronic 5-KETE exposure

    • Sequential challenge with inflammatory stimuli and oxidative stressors

    • Recovery phase monitoring

• In vivo models with dual readouts:

  • Zebrafish inflammation/redox models :

    • Live imaging of neutrophil recruitment

    • Simultaneous ROS detection with redox-sensitive probes

    • OXER1/hcar1-4 genetic manipulation

  • Human tissue explant cultures:

    • Comparison of normal vs. inflamed tissues

    • Ex vivo treatment with 5-KETE and oxidative stressors

    • Multi-parameter analysis of inflammatory and redox responses

• Molecular mechanism investigations:

  • Protein-protein interaction analysis:

    • OXER1 interactome under basal vs. stimulated conditions

    • Redox-dependent interaction changes

    • Identification of scaffolding proteins coordinating dual functions

  • Transcriptional network analysis:

    • ChIP-seq for redox-sensitive transcription factors

    • RNA-seq comparing inflammatory vs. oxidative stress responses

    • Integration with proteomics data

This comprehensive experimental approach will allow researchers to dissect how OXER1 coordinates both inflammatory responses and redox adaptation, potentially revealing new therapeutic opportunities for inflammatory and oxidative stress-related disorders.

How can researchers design experiments to investigate the potential role of OXER1 in cancer progression and therapy resistance?

Based on emerging evidence linking OXER1 to cancer , researchers should implement this experimental framework to investigate its roles in cancer progression and therapy resistance:

• Clinical correlation studies:

  • Expression analysis in patient cohorts:

    • Comprehensive IHC analysis of OXER1 in tumor microarrays

    • Correlation with clinical parameters (stage, grade, survival)

    • Multivariate analysis accounting for molecular subtypes

  • Genetic alteration screening:

    • Analysis of OXER1 mutations (e.g., S78Pfs*64 frameshift)

    • Copy number variation assessment

    • Promoter methylation status

• Functional phenotyping in cancer models:

  • Genetic manipulation approaches:

    Manipulation	Models	Phenotypic Readouts
    OXER1 knockdown	Prostate, breast cancer cell lines	Proliferation, migration, invasion, apoptosis
    OXER1 overexpression	Low-expressing cancer cells	Malignant transformation, metabolic changes
    OXER1 mutation	Introduction of cancer-associated variants	Functional consequences

  • In vivo cancer models:

    • Xenograft studies with OXER1-manipulated cells

    • Patient-derived xenografts with varied OXER1 expression

    • Analysis of tumor growth, metastasis, and redox status

• Therapy resistance mechanisms:

  • Treatment response correlation:

    • OXER1 expression before and after therapy

    • Comparison between responders and non-responders

    • Analysis in recurrent/resistant tumors

  • Drug resistance induction models:

    • Development of resistant cell lines via drug exposure

    • OXER1 expression/function changes during resistance acquisition

    • Reversal of resistance through OXER1 targeting

• Molecular pathway analysis:

  • Signaling network mapping:

    • PI3K/Akt/NF-κB pathway analysis

    • RACK1 regulation by OXER1

    • Integration with redox adaptation pathways

  • Metabolic reprogramming assessment:

    • Analysis of oxidative vs. glycolytic metabolism

    • Mitochondrial function in OXER1-manipulated cells

    • Stress response to metabolic inhibitors

• Therapeutic targeting strategies:

  • OXER1 antagonist evaluation:

    • Testing of identified polyphenolic antagonists

    • Development of novel, selective antagonists

    • Combination with conventional cancer therapies

  • Dual-targeting approaches:

    • Combined inhibition of OXER1 and downstream effectors

    • Targeting both inflammatory and redox adaptation roles

    • Exploitation of synthetic lethality relationships

This comprehensive experimental framework will enable researchers to thoroughly investigate OXER1's roles in cancer progression and therapy resistance, potentially leading to new therapeutic approaches targeting this receptor in cancer.

What are the most promising methodological approaches for investigating OXER1's role in the interaction between tumor cells and macrophages?

To effectively investigate OXER1's emerging role in tumor-macrophage interactions , researchers should employ these methodological approaches:

• Advanced co-culture systems:

  • 2D co-culture models:

    • Direct co-culture of tumor cells with macrophages

    • Transwell systems for soluble factor exchange

    • OXER1 knockdown/overexpression in specific cell populations

  • 3D co-culture technologies:

    • Tumor spheroids with infiltrating macrophages

    • Hydrogel-based 3D co-culture systems

    • Microfluidic devices with controlled spatial organization

  • Ex vivo tissue slice cultures:

    • Maintenance of intact tumor microenvironment

    • Introduction of labeled macrophages

    • Manipulation of OXER1 signaling with agonists/antagonists

• Macrophage polarization analysis:

  • Differentiation protocols:

    Macrophage Type	Differentiation Method	OXER1 Expression
    M0	THP-1 + PMA (50 nM, 48h)	Low levels
    M1	M0 + LPS (100 ng/ml) + IFNγ (20 ng/ml)	Higher levels
    M2	M0 + IL-4 (20 ng/ml) + IL-13 (20 ng/ml)	Higher levels

  • Comprehensive phenotyping:

    • Flow cytometry for surface markers

    • Cytokine/chemokine profiling

    • Gene expression analysis of polarization markers

    • OXER1 localization and function in each subtype

• Intercellular communication assessment:

  • Soluble mediator analysis:

    • Metabolomic analysis focusing on eicosanoids

    • 5-oxo-ETE production/consumption in co-cultures

    • Cytokine/chemokine network mapping

  • Direct cell-cell interaction:

    • Live cell imaging of tumor-macrophage contacts

    • Analysis of adhesion molecule expression

    • Signal transfer via tunneling nanotubes or exosomes

• In vivo models with cell-specific manipulation:

  • Syngeneic tumor models with macrophage targeting:

    • Clodronate liposome depletion of macrophages

    • Adoptive transfer of OXER1-manipulated macrophages

    • CSF1R inhibition to modify TAM populations

  • Cell-specific genetic approaches:

    • Conditional OXER1 knockout in macrophages or tumor cells

    • Cell type-specific reporter systems

    • Inducible expression systems for temporal control

• Mechanistic dissection of bidirectional signaling:

  • Tumor → Macrophage signaling:

    • Tumor-derived factors affecting macrophage OXER1 expression

    • Impact on macrophage recruitment and polarization

    • Induction of pro-tumor vs. anti-tumor phenotypes

  • Macrophage → Tumor signaling:

    • Macrophage-derived 5-oxo-ETE effects on tumor cells

    • RACK1/PI3K/Akt/NF-κB pathway activation in tumor cells

    • Changes in tumor cell proliferation, migration, and therapy resistance

• Translational approaches:

  • Multiplex imaging of human tumors:

    • Co-localization of OXER1 with macrophage markers

    • Spatial relationships in tumor microenvironment

    • Correlation with clinical outcomes

  • Ex vivo drug testing:

    • Patient-derived tumor/immune cell co-cultures

    • OXER1 antagonist effects on tumor-macrophage interactions

    • Combination with immunotherapies or targeted agents

These methodological approaches provide a comprehensive framework for investigating the complex role of OXER1 in mediating interactions between tumor cells and macrophages, potentially leading to new therapeutic strategies targeting this signaling axis.